Ann: June 2023 Quarterly Activities Report & Appendix 4C, page-26

Lambert Initiative has registered a new Phase 2 trial of 150mg dose CBD, due to commence on 4 September,

The study, which has already received ethics approval, will be a randomised, double-blind, placebo-controlled, parallel-group trial exploring the effect of purified oral cannabidiol (CBD) on psychosocial stress, situational anxiety, acute motion sickness and cybersickness experienced in a virtual reality environment in healthy individuals.

Target enrolment for the study is 74 participants.

The three virtual reality tests to be used include a “Walk the Plank” task and a “Rollercoaster Ride”.

Not sure why they don’t just recruit AVE shareholders

The intervention will be an acute dose of cannabidiol (CBD). Specifically, it will be 2 x soft-gel capsules of CBD (150mg total) in an oil-based formulation. The capsules will be consumed (once only) via oral ingestion under the supervision of an investigator 90-minutes prior to exposure to a series of three customised virtual reality (VR) experiences using the Vive Pro Eye VR headset including (1) a 15-minute simulated public speaking task, the "Public Speaking" task (2) a 5-minute task of walking a narrow virtual plank above a sheer drop, the "Walk the Plank" task; and (3) a 5-minute virtual reality rollercoaster ride, the "Rollercoaster Ride". Each VR task will be separated by a rest period of 10-minutes. Each participant will complete all three VR tasks after treatment (i.e., CBD or placebo) during individual "Test Days".

https://www.anzctr.org.au/Trial/Registration/TrialReview.aspx?id=386271&isReview=true